EUVIMEDEUVIMED entdecken
Crossref

Genomic landscape of comprehensive genomic profiling in patients with malignant solid tumors in Japan

Tatsuro Yamaguchi, Masachika Ikegami, Tomoyuki Aruga, Yusuke Kanemasa, Shin-Ichiro Horiguchi, Kazushige Kawai, Misato Takao, Takeshi Yamada, Hideyuki Ishida

International Journal of Clinical Oncology · 2024-10 · 29 (10) · 1417-1431

DOI: 10.1007/s10147-024-02554-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 25.05.2024. Verfasst von Tatsuro Yamaguchi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Genetics, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan. tatsuro@yamaguchi.email.ne…. Hauptthemen laut MEDLINE: Neoplasms, Genomics. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Comprehensive genomic profiling (CGP) can aid the discovery of clinically useful, candidate antitumor agents; however, the variant annotations sometimes differ among the various types of CGP tests as well as the public database. The aim of this study is to clarify the genomic landscape of evaluating detected variants in patients with a malignant solid tumor. METHODS: The present, cross-sectional study used data from 57,084 patients with a malignant solid tumor who underwent CGP at the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) between June 1, 2019 and August 18, 2023. The pathogenicity of the variants was annotated using public databases. RESULTS: As a result of re-annotation of the detected variants, 20.1% were pathogenic and 1.4% were benign. The mean number of pathogenic variants was 4.30 (95% confidence interval: 4.27-4.32) per patient. Of the entire cohort, 5.7% had no pathogenic variant. The co-occurrence of the genes depended on the tumor type. Germline findings were detected in 6.2%, 8.8%, and 15.8% of the patients using a tumor/normal panel, tumor-only panel, and liquid panel, respectively, with the most common gene being BRCA2 followed by TP53 and BRCA1. CONCLUSIONS: The detected variants should be re-annotated because several benign variants or variants of unknown significance were included in the CGP, and the genomic landscape derived from these results will help researchers and physicians interpret the results of CGP tests. The method of extracting presumptive, germline, pathogenic variants from patients using a tumor-only panel or circulating tumor DNA panel requires improvement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsGenomicsHumansMaleFemaleMiddle AgedCross-Sectional StudiesAgedJapanAdultAged, 80 and overYoung AdultBRCA2 ProteinBRCA1 ProteinGerm-Line MutationAdolescentTumor Suppressor Protein p53

Stichwörter der Autor:innen

AnnotationCancer genomicsComprehensive genomic profiling testGermline findingsMalignant solid tumor

Substanzen

BRCA2 protein, humanTP53 protein, humanBRCA2 ProteinBRCA1 protein, humanBRCA1 ProteinTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Department of Clinical Genetics, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan. tatsuro@yamaguchi.email.ne.jp.
  • Department of Clinical Genetics, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
  • Department of Musculoskeletal Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-Ku, Tokyo, 113-8677, Japan.
  • Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
  • Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
  • Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Yamaguchi, T., Ikegami, M., Aruga, T., Kanemasa, Y., Horiguchi, S. I., Kawai, K., Takao, M., Yamada, T., & Ishida, H. (2024). Genomic landscape of comprehensive genomic profiling in patients with malignant solid tumors in Japan. International Journal of Clinical Oncology, 29(10), 1417-1431. https://doi.org/10.1007/s10147-024-02554-8

Vancouver

Yamaguchi T, Ikegami M, Aruga T, Kanemasa Y, Horiguchi SI, Kawai K, et al. Genomic landscape of comprehensive genomic profiling in patients with malignant solid tumors in Japan. International Journal of Clinical Oncology. 2024;29(10):1417-1431. doi:10.1007/s10147-024-02554-8

BibTeX
@article{Yamaguchi2024,
  author = {Yamaguchi, Tatsuro and Ikegami, Masachika and Aruga, Tomoyuki and Kanemasa, Yusuke and Horiguchi, Shin-Ichiro and Kawai, Kazushige and Takao, Misato and Yamada, Takeshi and Ishida, Hideyuki},
  title = {Genomic landscape of comprehensive genomic profiling in patients with malignant solid tumors in Japan},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  volume = {29},
  number = {10},
  pages = {1417--1431},
  doi = {10.1007/s10147-024-02554-8}
}
Kostenlos starten →